The prognostic significance of antigen expression in leukaemia

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 4, 2003, Pages 613-628

  Schabath, Richard ^a   Ratei, Richard ^a   Ludwig, Wolf Dieter ^a  

^a Section of Pathology   (Germany)

Author keywords

Apoptosis regulating proteins; Drug resistance; Flow cytometry; Genotype phenotype associations; Immunophenotyping; Leukaemia; Prognosis

Indexed keywords

MEMBRANE ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; CANCER RISK; CELL LINEAGE; CELL MATURATION; FLOW CYTOMETRY; GENETIC DISORDER; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA CELL; MULTIDRUG RESISTANCE; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; DISEASE CLASSIFICATION; GENOTYPE PHENOTYPE CORRELATION;

EID: 0242521503     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00087-2     Document Type: Review

References (94)

1. Jennings CD & Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997; 90: 2863-2892.
2. Orfao, A, Schmitz G, Brando B et al. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clinical Chemistry 1999; 45: 1708-1717.
3. Béné MC, Bernier M, Castoldi G et al. Impact of immunophenotyping on management of acute leukemias. Haematologica 1999; 84: 1024-1034.
4. Ludwig WD, Haferlach T & Schoch C. Classification of acute leukemias: perspective I. In Pui CH (ed.) Treatment of Acute Leukemias: New Directions for Clinical Research. Totowa, NJ: Humana Press Inc, 2003, pp 3-41.
5. Behm F. Classification of acute leukemias: perspective 2. In Pui CH (ed.) Treatment of Acute Leukemias: New Directions for Clinical Research. Totowa, NJ: Humana Press Inc, 2003, pp 43-58.
6. Campana D & Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukemia. Clinical Haematology 2002; 15: 1-19.
7. Schimmer AD, Hedley DW, Penn LZ & Minden MD. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 2001; 98: 3541-3553.
8. Béné MC, Castoldi G, Knapp W et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
9. Paietta E, Andersen J & Wiernik PH. A new approach to analyzing the utility of immunophenotyping for predicting clinical outcome in acute leukemia. Eastern Cooperative Oncology Group. Leukemia 1996; 10: 1-4.
10. Rothe G & Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia 1996; 10: 877-895.
11. Davis BH, Foucar K, Szczarkowski W et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. Cytometry 1997; 30: 249-263.
12. Paietta E, Andersen J, Yunis J et al. Acute myeloid leukemia expressing the leucocyte integrin CD11b - a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology Group. British Journal of Haematology 1998; 100: 265-272.
13. Porwit MacDonald A, Janossy G, Ivory K et al. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 1996; 87: 1162-1169.
14. De Zen L, Orfao, A, Cazzaniga G et al. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. 1. ETV6/AML1 ALLs identification. Leukemia 2000; 14: 1225-1231.
15. Tabernero MD, Bortoluci AM, Alaejos I et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia 2001; 15: 406-414.
16. Hrusak O & Porwit MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002; 16: 1233-1258.
17. Ludwig WD, Raghavachar A & Thiel E. Immunophenotypic classification of acute lymphoblastic leukemia. Baillière's Clinical Haematology 1994; 7: 235-262.
18. WHO, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.
19. Raimondi SC, Behm FG, Roberson PK et al. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). Journal of Clinical Oncology 1990; 8: 1380-1388.
20. Hoelzer D, Ludwig WD, Thiel E et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508.
21. Czuczman MS, Dodge RK, Stewart CC et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999; 93: 3931-3939.
22. Reiter A, Schrappe M, Tiemann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94: 3294-3306.
23. Ludwig WD, Rieder H, Bartram CR et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909.
24. Uckun FM, Sather H, Gaynon P et al. Prognostic significance of the CD10 + CD19 + CD34 + B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leukemia & Lymphoma 1997; 27: 445-457.
25. -) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucemies. Leukemia & Lymphoma 1998; 28: 329-342.
26. Consolini R, Legitimo A, Rondelli R et al. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica 1998; 83: 967-973.
27. Pui CH & Evans WE. Acute lymphoblastic leukemia. New England Journal of Medicine 1998; 339: 605-615.
28. Crist W, Boyett J, Jackson J et al. Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Ontology Group study. Blood 1989; 74: 1252-1259.
29. Ludwig WD, Harbott J, Bartram CR et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. Recent Results in Cancer Research 1993; 131: 269-282.
30. Hann IM, Richards SM, Eden OB & Hill FG. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukemia Working Party. Leukemia 1998; 12: 1249-1255.
31. Ratei R, Sperling C, Karawajew L et al. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia. Annals of Hematology 1998, 77: 107-114.
32. Uckun FM, Sensel MG, Sun L et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 735-746.
33. Crist WM, Shuster JJ, Falletta J et al. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. Blood 1988; 72: 1891-1897.
34. -)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 1989; 73: 1247-1258.
35. Niehues T, Kapaun P, Harms DO et al. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favourable outcome in the COALL studies. Leukemia 1999; 13: 614-617.
36. Pullen J, Shuster JJ, Link M et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Ontology Group (POG) study. Leukemia 1999; 13: 1696-1707.
37. Karawajew L, Ruppert V, Wuchter C et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with upregulation of Bcl-2, cortical/mature immunophenotype, and better early cytoreduction in childhood T-ALL. Blood 2000; 96: 297-306.
38. Wuchter C, Ruppert V, Schrappe M et al. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood 2002; 99: 4109-4115.
39. Ferrando AA, Neuberg DS, Staunton J et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
40. Campana D, van Dongen JJ, Mehta A et al. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood 1991; 77: 1546-1554.
41. Alfsen GC, Beiske K, Holte HT et al. T-cell receptor gammadelta + /CD3+4-8- T-cell acute lymphoblastic leukemias: a distinct subgroup of leukemias in children. A report of five cases. Blood 1991; 77: 2023-2030.
42. Schott G, Sperling C, Schrappe M et al. Immunophenotypic and clinical features of T-cell receptor gammadelta+ T-lineage acute lymphoblastic leukemia. British Journal of Haematology 1998; 101: 753-755.
43. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 2000; 14: 467-473.
44. Maung ZT, MacLean FR, Reid MM et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. British Journal of Haematology 1994; 88: 105-109.
45. Faderl S & Estrov Z. The clinical significance of caspase regulation in acute leukemia. Leukemia & Lymphoma 2001; 40: 471-481.
46. Bennett JM, Catovsky D, Daniel MT et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Annals of Internal Medicine 1985; 103: 460-462.
47. Bennett JM, Catovsky D, Daniel MT et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). British Journal of Haematology 1991; 78: 325-329.
48. Orfao A, Vidriales B, Gonzalez M et al. Diagnostic and prognostic importance of immunophenotyping in adults with acute myeloid leukemia. In: Recent Results in Cancer Research 1993; 131: 369-379.
49. Borowitz MJ, Guenther KL, Shults KE & Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukaemic blasts in three-color analysis. American Journal of Clinical Pathology 1993; 100: 534-540.
50. Smith FO, Lampkin BC, Versteeg C et al. Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance. Blood 1992; 79: 2415-2422.
51. Kuerbitz SJ, Civin CI, Krischer JP et al. Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: a Pediatric Oncology Group study. Journal of Clinical Oncology 1992; 10: 1419-1429.
52. Creutzig U, Harbott J, Sperling C et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995; 86: 3097-3108.
53. - phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 1992; 6: 393-399.
54. Del Poeta G, Stasi R, Venditti A et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994; 8: 388-394.
55. Bradstock K, Matthews J, Benson E et al. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukemia Study Group. Blood 1994; 84: 1220-1225.
56. Schwarzinger I, Valent P, Köller U et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. Journal of Clinical Oncology 1990; 8: 423-430.
57. Ball ED, Davis RB, Griffin JD et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991; 77: 2242-2250.
58. Sperling C, Büchner T, Creutzig U et al. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. Leukemia & Lymphoma 1995; 17: 417-426.
59. Legrand O, Perrot JY, Baudard M et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870-877.
60. Wuchter C, Karawajew L, Ruppert V et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de nova acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999; 13: 1943-1953.
61. Cuneo A, Michaux JL, Ferrant A et al. Correlation of cytogenetic patterns and clinicobiological features in adult acute myeloid leukemia expressing lymphoid markers. Blood 1992; 79: 720-727.
62. Reading CL, Estey EH, Huh YO et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083-3090.
63. Baer MR, Stewart CC, Lawrence D et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997; 90: 1643-1648.
64. Murray CK, Estey E, Paietta E et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? Journal of Clinical Oncology 1999; 17: 293-297.
65. Baer MR, Stewart CC, Lawrence D et al. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia 1998; 12: 317-325.
66. Sperling C, Schwartz S, Büchner T et al. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica 1997; 82: 617-621.
67. Schwartz S, Heinecke A, Zimmermann M et al. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leukemia & Lymphoma 1999; 34: 85-94.
68. Cuneo A, Ferrant A, Michaux JL et al. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood 1995; 85: 3688-3694.
69. Venditti A, Del Poeta G, Buccisano F et al. Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. Blood 1997; 89: 621-629.
70. Béné MC, Bernier M, Casasnovas RO et al. Acute myeloid leukemia MO: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. British Journal of Haematology 2001; 113: 737-745.
71. Stasi R, Del Poeta G, Venditti A et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 1994; 83: 1619-1625.
72. Cohen PL, Hoyer JD, Kurtin PJ et al. Acute myeloid leukemia with minimal differentiation. A multiple parameter study. American Journal of Clinical Pathology 1998; 109: 32-38.
73. Legrand O, Simonin G, Perrot JY et al. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480-4488.
74. Kasimir Bauer S, Beelen D, Flasshove M et al. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Experimental Hematology 2002; 30: 1302-1308.
75. Del Poeta G, Venditti A, Del Principle MI et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101: 2125-2131.
76. Tamm I, Kornblau SM, Segall H et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clinical Cancer Research 2000; 6: 1796-1803.
77. Béné MC, Bernier M, Casasnovas RO et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998; 92: 596-599.
78. Hanson CA, Abaza M, Sheldon S et al. Acute biphenotypic leukemia: immunophenotypic and cytogenetic analysis. British Journal of Haematology 1993; 84: 49-60.
79. Carbonell F, Swansbury J, Min T et al. Cytogenetic findings in acute biphenotypic leukemia. Leukemia 1996; 10: 1283-1287.
80. Matutes E, Morilla R, Farahat N et al. Definition of acute biphenotypic leukemia. Haematologica 1997; 82: 64-66.
81. Legrand O, Perrot JY, Simonin G et al. Adult biphenotypic acute leukemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. British Journal of Haematology 1998; 100: 147-155.
82. Drexler HG & Ludwig WD. Incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Recent Results in Cancer Reseach 1993; 131: 53-66.
83. Drexler HG, Thiel E & Ludwig WD. Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. Leukemia 1993; 7: 489-498.
84. Khalidi HS, Chang KL, Medeiros; LJ et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. American Journal of Clinical Pathology 1999; 111: 467-476.
85. Uckun FM, Sather HN, Gaynon PS et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1997; 90: 28-35.
86. Putti MC, Rondelli R, Cocito MG et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 1998; 92: 795-801.
87. Pui CH, Rubnitz R, Hancock ML et al. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 1998; 16: 3768-3773.
88. Ludwig WD, Harbott J, Rieder H, et al. Incidence, biologic features and treatment outcome of myeloid-antigen-positive acute lymphoblastic leukemia (My + ALL). In Büchner T, et al. (eds) Acute Leukemias IV. Prognostic Factors. Berlin: Springer, 1994, pp 24.
89. Ogata K, Yokose N, Shioi Y et al. Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukemia. British Journal of Haematology 2001; 115: 612-615.
90. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
91. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998; 83: 1104-1115.
92. Stetler Stevenson M, Arthur DC, Jabbour N et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-987.
93. Maynadie M, Picard F, Husson B et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002; 100: 2349-2356.
94. Ogata K, Nakamura K, Yokose N et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 3887-3896.